Harrow, Inc. Impairment of Long-Lived Assets Held-for-use
Harrow, Inc. (HROW) reported Impairment of Long-Lived Assets Held-for-use of $253.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-03-02
- Harrow, Inc. impairment of long-lived assets held-for-use for the quarter ending 2020-12-31 was $0.00.
- Harrow, Inc. impairment of long-lived assets held-for-use for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- Harrow, Inc. impairment of long-lived assets held-for-use for the quarter ending 2020-06-30 was $363.00K.
- Harrow, Inc. impairment of long-lived assets held-for-use for the quarter ending 2019-12-31 was $0.00.
- Harrow, Inc. impairment of long-lived assets held-for-use for fiscal 2024 was $253.00K, a 33.42% decline from fiscal 2023.
- Harrow, Inc. impairment of long-lived assets held-for-use for fiscal 2023 was $380.00K.
- Harrow, Inc. impairment of long-lived assets held-for-use for fiscal 2021 was $249.00K, a 31.40% decline from fiscal 2020.
- Harrow, Inc. impairment of long-lived assets held-for-use for fiscal 2020 was $363.00K, a 91.01% decline from fiscal 2019.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|
| 2024-12-31 | $253.00K 10-K · filed 2026-03-02 | |||
| 2023-12-31 | $380.00K 10-K · filed 2026-03-02 | |||
| 2021-12-31 | $249.00K 10-K · filed 2023-03-23 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $0.00 derived: sum of 2 quarters · filed 2022-03-10 | $363.00K derived: sum of 3 quarters · filed 2022-03-10 | $363.00K 10-K · filed 2022-03-10 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $363.00K derived: sum of 2 quarters · filed 2021-11-09 | $363.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $363.00K 10-Q · filed 2021-08-10 | $363.00K 10-Q · filed 2021-08-10 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $4.04M derived: sum of 2 quarters · filed 2021-03-08 | $4.04M 10-K · filed 2021-03-08 | |
| 2019-09-30 | $4.04M 10-Q · filed 2020-11-09 | $4.04M 10-Q · filed 2020-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |